Masimo Corp (MASI)
160.15
-1.53
(-0.95%)
USD |
NASDAQ |
Nov 14, 16:00
160.13
-0.02
(-0.01%)
After-Hours: 20:00
Masimo Research and Development Expense (Quarterly): 48.30M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 48.30M |
| June 30, 2024 | 49.00M |
| March 31, 2024 | 47.80M |
| December 31, 2023 | 38.00M |
| September 30, 2023 | 46.50M |
| June 30, 2023 | 40.20M |
| March 31, 2023 | 50.50M |
| December 31, 2022 | 54.30M |
| September 30, 2022 | 53.10M |
| June 30, 2022 | 47.80M |
| March 31, 2022 | 36.10M |
| December 31, 2021 | 33.30M |
| September 30, 2021 | 35.40M |
| June 30, 2021 | 33.90M |
| March 31, 2021 | 34.51M |
| December 31, 2020 | 31.73M |
| September 30, 2020 | 28.85M |
| June 30, 2020 | 30.88M |
| March 31, 2020 | 27.24M |
| December 31, 2019 | 23.42M |
| September 30, 2019 | 24.28M |
| June 30, 2019 | 24.18M |
| March 31, 2019 | 21.42M |
| December 31, 2018 | 20.79M |
| September 30, 2018 | 20.58M |
| Date | Value |
|---|---|
| June 30, 2018 | 20.08M |
| March 31, 2018 | 19.56M |
| December 31, 2017 | 19.38M |
| September 30, 2017 | 15.30M |
| June 30, 2017 | 16.38M |
| March 31, 2017 | 14.18M |
| December 31, 2016 | 12.83M |
| September 30, 2016 | 15.67M |
| June 30, 2016 | 14.82M |
| March 31, 2016 | 14.36M |
| December 31, 2015 | 13.81M |
| September 30, 2015 | 14.48M |
| June 30, 2015 | 13.39M |
| March 31, 2015 | 14.93M |
| December 31, 2014 | 15.03M |
| September 30, 2014 | 14.21M |
| June 30, 2014 | 13.34M |
| March 31, 2014 | 14.00M |
| December 31, 2013 | 13.94M |
| September 30, 2013 | 13.65M |
| June 30, 2013 | 13.88M |
| March 31, 2013 | 14.17M |
| December 31, 2012 | 13.34M |
| September 30, 2012 | 12.12M |
| June 30, 2012 | 11.11M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
23.42M
Minimum
Dec 2019
54.30M
Maximum
Dec 2022
39.54M
Average
37.05M
Median
Research and Development Expense (Quarterly) Benchmarks
| Boston Scientific Corp | 407.00M |
| Baxter International Inc | 129.00M |
| AngioDynamics Inc | 6.285M |
| Accuray Inc | 12.12M |
| Tandem Diabetes Care Inc | 51.11M |